Published by MyelinWatch:
Low-dose theophylline patch · The team is refining a low-dose skin patch intended to deliver theophylline and affect HDAC2, a protein linked to myelin repair.
The team is refining a low-dose skin patch intended to deliver theophylline and affect HDAC2, a protein linked to myelin repair.
Not tested in people
Work remains in the laboratory and product development; a first safety study is planned.
Current work concerns laboratory findings and patch development. A safety study in healthy volunteers is planned but has not been shown to have started.
This is early laboratory work, not a treatment for people with MS. A planned volunteer study would first address safety, not benefit in MS.
Claire Jacob's team at Johannes Gutenberg University Mainz announced €1.1 million to improve the skin patch, manufacture it to pharmaceutical standards and prepare a first safety study in healthy volunteers.
Source: Johannes Gutenberg University Mainz — official university research update ↗
